Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business
7th US Indication For The JAK Inhibitor, 2nd In IBD
US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira.
You may also be interested in...
AbbVie's Rinvoq Succeeds Against The Odds In Phase II Lupus Trial
Despite a troubled history of JAK inhibitors in lupus trials, AbbVie’s Rinvoq has hit the mark in a mid-stage study of the condition, shifting focus to a pivotal program that could expand the blockbuster drug’s reach.
FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.
AbbVie Gets Humira Erosion Right, But Skyrizi/Rinvoq Disappoint Investors
Humira’s US revenue declines by 26% as biosimilar adalimumab makes its debut. Follow-ons Skyrizi and Rinvoq post strong growth, but fall short of Street consensus estimates.